Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chemotherapy delivery

This article was originally published in The Gray Sheet

Executive Summary

Delcath Systems awaits FDA protocol approval to initiate its planned Phase III clinical trial for its catheter-based perfusion technology to deliver the chemotherapy drug melphalan after the trial was cleared by the National Cancer Institute Institutional Review Board Feb. 7. The Delcath system delivers high-dose chemotherapy directly to the liver via the hepatic artery and includes special filters that block the rest of the body from excessive toxicity, according to the firm...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT023204

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel